Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice

European Journal of Haematology
Evangelos TerposMeletios Dimopoulos

Abstract

The efficacy and safety of bortezomib-based therapy for relapsed/refractory multiple myeloma (RRMM) in clinical trials may differ from the oncology practice experience. The electronic VELCADE® OBservational Study was designed to prospectively evaluate bortezomib for multiple myeloma (MM) in real-world medical practice. Patients scheduled to receive intravenous bortezomib for MM were eligible. The primary objective was to evaluate clinical outcomes, including response, time to response, time to next therapy, treatment-free interval, progression-free survival (PFS), and overall survival (OS). Secondary objectives included safety and healthcare resource utilization. In total, 873 patients with a median of two therapy lines prior to initiating bortezomib were included. The overall response rate (≥partial response) was 69%, including 37% complete response/near-complete response. Median time to response was 1.8 months, median time to next therapy was 9.7 months, and median treatment-free interval was 7.9 months. After 22.6 months' median follow-up, median PFS was 12.0 months and median OS was 36.1 months. The most common adverse events (AEs) were neuropathy not otherwise specified (19%), diarrhea NOS, and thrombocytopenia (each 17%);...Continue Reading

References

Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Jul 13, 2004·Mayo Clinic Proceedings·Shaji K KumarPhilip R Greipp
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
May 13, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-L HarrouseauUNKNOWN ESMO Guidelines Task Force
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiJean-Luc Harousseau
Jun 26, 2012·Seminars in Hematology·Prashant KapoorS Vincent Rajkumar
Jan 12, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·Kenneth C AndersonRashmi Kumar
Jul 3, 2013·Leukemia & Lymphoma·Annie Fourrier-RéglatUNKNOWN VESUVE Study Group
Apr 17, 2015·Oncology Research and Treatment·Wolfgang KnaufAndreas Schwarzer
Sep 24, 2015·Leukemia & Lymphoma·Angela GrelaudUNKNOWN VESUVE Study Group
Apr 28, 2016·The New England Journal of Medicine·Philippe MoreauUNKNOWN TOURMALINE-MM1 Study Group
Jul 14, 2016·British Journal of Haematology·Kwee YongMichele Cavo
Oct 28, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Mohamed TouatiDominique Bordessoule
Aug 25, 2016·The New England Journal of Medicine·Antonio PalumboUNKNOWN CASTOR Investigators
Nov 20, 2016·European Journal of Haematology·Helgi van de VeldeJesse A Berlin
Nov 20, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Robert F CornellParameswaran Hari
Feb 17, 2017·Therapeutic Advances in Hematology·Shahzad RazaSuzanne Lentzsch
Feb 17, 2017·Journal of Internal Medicine·O Landgren, K Iskander

❮ Previous
Next ❯

Citations

Aug 29, 2020·Therapeutic Innovation & Regulatory Science·Alfredo Aram PuliniGregory Katz
Jan 31, 2019·Health Science Reports·Cyrille HulinMichel Delforge
Mar 15, 2021·Clinical Lymphoma, Myeloma & Leukemia·Ioannis Ntanasis-StathopoulosMeletios A Dimopoulos
Jun 3, 2021·International Journal of Molecular Sciences·Tomáš KycaMário Šereš

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.